{"groups":[{"description":"Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.","id":"FG000","title":"Belzutifan"},{"description":"Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.","id":"FG001","title":"Everolimus"},{"description":"Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.","id":"FG002","title":"Safety Run-In"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"245"},{"groupId":"FG001","numSubjects":"253"},{"groupId":"FG002","numSubjects":"5"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"110"},{"groupId":"FG002","numSubjects":"4"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"374"},{"groupId":"FG001","numSubjects":"372"},{"groupId":"FG002","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"372"},{"groupId":"FG001","numSubjects":"360"},{"groupId":"FG002","numSubjects":"9"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"374"},{"groupId":"FG001","numSubjects":"372"},{"groupId":"FG002","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures."}